RWE Aktiengesellschaft

  • WKN: 703712
  • ISIN: DE0007037129
  • Land: Deutschland

Nachricht vom 09.09.2021 | 09:59

RWE Aktiengesellschaft: Release of a capital market information

RWE Aktiengesellschaft / Share Buyback
09.09.2021 / 09:59
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification in accordance with Article 5, para. 1 lit. b) and para. 3 of Regulation (EU) 596/2014 and Article 2, para. 3 of Delegated Regulation (EU) 2016/1052

On 22 December 2020 RWE Aktiengesellschaft announced share buyback programs of RWE Supply & Trading GmbH UK Branch, RWE Generation UK plc and RWE Technology UK Limited pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) no. 596/2014 in connection with Art. 2 para. 1 of the Delegated Regulation (EU) 2016/1052 of the Commission.

In September 2021 Computershare Trustees Limited as the independent Trustee acquired on behalf of RWE Supply & Trading GmbH UK Branch, RWE Generation UK plc and RWE Technology UK Limited a total of 475 shares of RWE Aktiengesellschaft under the currently conducted share buyback programs. The average purchase price paid on the stock market was GBP 29.305083. The company bought back shares for a total price of GBP 13,919.914 (excluding ancillary costs).

The acquisition of shares of RWE Aktiengesellschaft was exclusively executed in the stock market at Frankfurt Stock Exchange (XFRA).

Detailed information on the transactions pursuant to Art. 2 para. 3 of the Delegated Regulation (EU) 2016/1052 of the Commission is published in the 'Investor Relations' section on RWE Aktiengesellschaft's website (http://www.rwe.com/).



09.09.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021